Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
Business & Industry
- Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19
- Moderna announces primary efficacy analysis in Phase 3 COVE study for its COVID-19 vaccine candidate and filing today with U.S. FDA for Emergency Use Authorization
- Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19
- AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
- Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine
Research & Development
- Study finds metformin reduced COVID-19 death risks in women
- KU Leuven vaccine candidate protects against COVID-19 and yellow fever
- UK medicines regulator gives approval for first UK COVID-19 vaccine
- Predict cellular drug targets against COVID-19
- Doctors use existing treatment earlier to save the lives of COVID-19 patients
- European Commission approves contract with Moderna to ensure access to a potential vaccine
- New therapy for flu may help in fight against COVID-19
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
- EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine
- FDA authorizes monoclonal antibodies for treatment of COVID-19
- FDA approves first treatment for COVID-19
- EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation